Targeted Molecular Therapeutics for Parkinson's Disease: A Role for Antisense Oligonucleotides?

被引：4
作者：
Li, Dunhui [1 ,2 ,3 ]
Mastaglia, Frank L. [1 ,2 ]
Yau, Wai Yan [1 ]
Chen, Shengdi [4 ,5 ]
Wilton, Steve D. [1 ,2 ]
Akkari, Patrick A. [1 ,2 ,6 ]
机构：
[1] Univ Western Australia, Perron Inst Neurol & Translat Sci, 8 Verdun St, Nedlands, WA 6009, Australia
[2] Murdoch Univ, Ctr Mol Med & Innovat Therapeut, Murdoch, WA, Australia
[3] Zhengzhou Univ, Coll Nursing & Hlth, Zhengzhou, Peoples R China
[4] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Neurol, Sch Med, Shanghai, Peoples R China
[5] Shanghai Jiao Tong Univ, Ruijin Hosp, Inst Neurol, Sch Med, Shanghai, Peoples R China
[6] Duke Univ, Dept Neurol, Durham, NC USA
来源：
MOVEMENT DISORDERS | 2022年 / 37卷 / 11期
基金：
中国国家自然科学基金;
关键词：
D O I：
10.1002/mds.29201
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：2184 / 2190
页数：7
相关论文
共 50 条
[41]   Antisense oligonucleotides as molecular tools to silence prolonged (CAG)n tracts in Huntington's disease [J].
Vlamings, R. ;
Evers, M. M. ;
van Roon-Mom, W. M. C. ;
Mulders, S. A. M. ;
Janssen, M. L. F. ;
Verheul, R. C. ;
van Deutekom, J. C. T. ;
Temel, Y. .
MOVEMENT DISORDERS, 2012, 27 :S61-S61
[42]   LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson's Disease Mouse Model [J].
Zhao, Hien Tran ;
John, Neena ;
Delic, Vedad ;
Ikeda-Lee, Karli ;
Kim, Aneeza ;
Weihofen, Andreas ;
Swayze, Eric E. ;
Kordasiewicz, Holly B. ;
West, Andrew B. ;
Volpicelli-Daley, Laura A. .
MOLECULAR THERAPY-NUCLEIC ACIDS, 2017, 8 :508-519
[43]   Mitochondrial therapeutics in Alzheimer's disease and Parkinson's disease [J].
Hoekstra, Jake G. ;
Montine, Kathleen S. ;
Zhang, Jing ;
Montine, Thomas J. .
ALZHEIMERS RESEARCH & THERAPY, 2011, 3 (03)
[44]   Mitochondrial therapeutics in Alzheimer's disease and Parkinson's disease [J].
Jake G Hoekstra ;
Kathleen S Montine ;
Jing Zhang ;
Thomas J Montine .
Alzheimer's Research & Therapy, 3
[45]   Reusable solid-phase supports for oligonucleotides and antisense therapeutics [J].
Pon, RT ;
Yu, SY ;
Guo, ZQ ;
Deshmukh, R ;
Sanghvi, YS .
JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 1, 2001, (20) :2638-2643
[46]   Antisense Oligonucleotides as Therapeutics for Difficult-to-Drug Targets in Oncology [J].
Denker, Andrew .
MOLECULAR CANCER THERAPEUTICS, 2024, 23 (11)
[47]   Nano drug delivery systems for antisense oligonucleotides (ASO) therapeutics [J].
Ramasamy, Thiruganesh ;
Ruttala, Hima Bindu ;
Munusamy, Shankar ;
Chakraborty, Nilay ;
Kim, Jong Oh .
JOURNAL OF CONTROLLED RELEASE, 2022, 352 :861-878
[48]   Antisense Oligonucleotides Targeting Angiogenic Factors as Potential Cancer Therapeutics [J].
Le, Bao T. ;
Raguraman, Prithi ;
Kosbar, Tamer R. ;
Fletcher, Susan ;
Wilton, Steve D. ;
Veedu, Rakesh N. .
MOLECULAR THERAPY-NUCLEIC ACIDS, 2019, 14 :142-157
[49]   Gapmer Oligonucleotides: Sugar-Modified Wings to Antisense Therapeutics [J].
Rungta, Pallavi ;
Mangla, Priyanka ;
Sharma, Vivek K. ;
Singh, Sunil K. ;
Chauhan, Aman ;
Masram, Dhanraj T. ;
Senapati, Nihar Nalini ;
Prasad, Ashok K. .
TRENDS IN CARBOHYDRATE RESEARCH, 2015, 7 (03) :28-43
[50]   RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs [J].
Bajan, Sarah ;
Hutvagner, Gyorgy .
CELLS, 2020, 9 (01)
12345